ASP Isotopes Forecasts $300M EBITDA by 2031 as Helium and Nuclear Divisions Accelerate — ASP Isotopes Inc.

Event summary

ASP Isotopes forecasts $300M+ EBITDA by 2031, driven by helium and nuclear divisions.
PET Labs revenue grew 50% YoY in 1H 2026, targeting $14M for FY 2026.
Helium production at Renergen to commence before September 30, 2026, with $27M annualized revenue expected post-Phase 1.
Silicon-28 and Ytterbium-176 enrichment facilities to ship initial products in 2H 2026.
Renergen's Phase 2 construction planned for 2H 2026, targeting $360M annual revenue at nameplate capacity.

The big picture

ASP Isotopes is positioning itself as a critical player in the global supply of helium and nuclear fuels, leveraging strategic acquisitions and long-term contracts to secure its revenue streams. The company's focus on high-growth divisions like PET Labs and Renergen underscores its shift towards a more diversified and resilient business model amid geopolitical uncertainties in the helium market.

What we're watching

Helium Market Dynamics: The pace at which global helium supply constraints will impact ASP Isotopes' revenue growth and contract negotiations.
Execution Risk: Whether ASP Isotopes can sustain its projected EBITDA targets given the delays in stable isotope division and equipment performance issues.
Strategic Repositioning: How the planned reverse merger with ENDRA Life Sciences will affect Renergen's market positioning and investor perception.